Related Experiment Videos
[Protein C deficiency and the P pill]
T Gundersen1, A L Gjennestad, O R Odegaard
1Medisinsk avdeling, Aker sykehus, Oslo.
Summary
Inherited protein C deficiency combined with estrogen contraceptives significantly increases the risk of dangerous blood clots, including pulmonary embolism. This genetic predisposition requires careful consideration in young women using hormonal treatments.
Area of Science:
- Genetics
- Hematology
- Pharmacology
Background:
- Inherited thrombophilias, such as protein C deficiency, predispose individuals to venous thromboembolism (VTE).
- Estrogen-containing contraceptives are a known risk factor for VTE.
- The interaction between genetic predisposition and exogenous hormones in VTE development warrants investigation.
Observation:
- An 18-year-old woman presented with inferior vena cava thrombosis, renal vein thrombosis, and pulmonary embolism.
- Her condition was attributed to a combination of inherited protein C deficiency and three months of estrogen-based oral contraceptive use.
- Protein C deficiency was identified in 12 additional family members, indicating a hereditary pattern.
Findings:
- The patient's VTE events were directly linked to the synergistic effect of inherited protein C deficiency and estrogen therapy.
- A significant family history of VTE, including a paternal pulmonary embolism and potential deaths from thromboembolism, underscores the genetic risk.
Implications:
- This case highlights the critical need for screening for inherited thrombophilias in young patients experiencing VTE, especially when initiating estrogen therapy.
- Physicians should carefully assess the risks and benefits of oral contraceptives in individuals with a known or suspected history of thrombophilia.
- Genetic counseling and long-term anticoagulation strategies may be necessary for affected families to prevent recurrent thromboembolic events.